{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T23:35:42Z","timestamp":1786232142479,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.lungcan.2024.107506","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:14:41Z","timestamp":1708168481000},"page":"107506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non\u2013small cell lung cancer: KEYNOTE-782"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":false,"given":"Jair","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Ponce","family":"Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Szalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gottfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman Bannur","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Townson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Dettman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Hunkapiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McDaniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoungsok","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Mauntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u0151szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2024.107506_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2024.107506_b0010","doi-asserted-by":"crossref","unstructured":"R.S. Herbst, G. Lopes, D.M. Kowalski, M. Nishio, Y.-L. Wu, G. de Castro Junior, P. Baas, D.-W. Kim, M.A. Gubens, R. Cristescu, D. Aurora-Garg, A. Albright, M. Ayers, A. Loboda, J. Lunceford, J. Kobie, G.M. Lubiniecki, M.C. Pietanza, B. Piperdi, T.S.K. Mok, Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials, in: LBA79 (Ed.) Ann Oncol 30 (Suppl 5) (2019) V916\u2013V917.","DOI":"10.1093\/annonc\/mdz394.077"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107506_b0015","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107506_b0020","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107506_b0025","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC","volume":"4","author":"Garassino","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2024.107506_b0030","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1200\/JCO.2020.38.15_suppl.9521","article-title":"Evaluation of blood TMB (bTMB) in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC","volume":"38","author":"Garassino","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107506_b0035","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107506_b0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.107506_b0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2024.107506_b0050","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:33Z","timestamp":1759237593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224000394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":10,"alternative-id":["S0169500224000394"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107506","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non\u2013small cell lung cancer: KEYNOTE-782","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107506"}}